DyslipidemiasNCT04894318
The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients
A study testing Low-fat and low-cholesterol diet in people with Dyslipidemias, run by TC Erciyes University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to compare LDL sub-group concentration before and after a diet with low-fat and low-cholesterol prescribed to dyslipidemic patients for 12 weeks. Read more about this study
- Who is it for?
- Ages 25 to 65 years
- Conditions the study is for
- Dyslipidemias
- What is being tested?
- Low-fat and low-cholesterol diet
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 Sep 2017to 25 Jul 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Being diagnosed with dyslipidemia by an endocrinologist
- Those who do not have a history of diabetes, hyperthyroidism, hypothyroidism (including those who have hypothyroidism but receive replacement therapy)
- 25-65 years
- Body Mass Index (BMI) = 25-40 kg/m²
- Smoking three or less than three cigarettes a day
- Not using herbal supplements.
- Not being in pregnancy or lactation period
- Volunteering to participate in the study
Who cannot join
- Not being diagnosed with dyslipidemia
- Using a drug that affects the lipid profile
- Not being in the age range of 25-65
- BMI = 25-40 kg/m² not
- Smoking more than three cigarettes a day
- Using herbal supplements
- Being in the pregnancy or lactation period
- Not willing to participate in the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Short Term Beneficıal Effects Of A Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Dyslipidemic Turkish Patients
The aim of this study is to compare LDL sub-group concentration before and after a diet with low-fat and low-cholesterol prescribed to dyslipidemic patients for 12 weeks.
Read the detailed description
The study was conducted between January 2018-July 2019 in Erciyes University Health Application and Research Center. This study was planned as a clinical trial for treatment and 47 patients were included. All participants were given written consent. The study was evaluated to be ethically appropriate by Erciyes University Faculty of Medicine Clinical Research Ethics Committee.
A low-fat (<30% of total energy), and low-cholesterol (<200 mg/day) diet was planned for the participants at the baseline, according to the gender, lifestyle, working conditions, nutritional habits, BMI, concomitant diseases and risk conditions. The patients were called for monthly controls and followed up for a total of 12 weeks. When the patients admitted at the first and second months, Body Impedance Analyzer (BIA) measurements were performed and dietary adherence was controlled. If necessary, the energy requirements of the patients were re-calculated and their diets were re-newed and if the patients had any questions on the diet, they were answered. Blood samples were taken from the patients at the baseline and after 12 weeks and the effects of a low-fat, low-cholesterol diet on biochemical and anthropometric measurements were evaluated. Energy restricted diet were planed for overweight and obese patients (~ 500-1000 kcal/day). In addition, patients were recommended to walk at a moderate speed for at least 30-40 min per day.
Data Collection A questionnaire including socio-demographic characteristics, nutritional habits, physical activity status, and comorbid diseases was filled by the researcher. The food consumption frequency of the participants was evaluated by dividing the frequencies into four groups as consuming 5-6 times daily, consuming every other day, consuming 1-2 times a week and consuming 1-2 times a month or never at all. Food consumption records were also taken from each patient. Physical activity was questioned by the 'International Physical Activity Questionnaire (short form).
Statistical analysis The suitability of the data for normal distribution was evaluated by histogram, q-q graphs and Shapiro-Wilk test. Variance homogeneity was tested with Levene test. Two groups independent samples t-test and Mann-Whitney U-tests were used for quantitative variables. In the qualitative data, two repeated measurement comparisons were used with McNemar-Bowker test. The paired t-test and Wilcoxon tests were used in the quantitative data for two repeated measurements. Spearman analysis was used to evaluate the relationship between quantitative variables. Data analysis was performed by Turcosa Cloud (Turcosa Ltd Co) statistical software. Significance level was accepted as p<0.05.
Anthropometric measurements After the completing the questionnaire, anthropometric measurements were taken. Body weight: When the patient was in fasting state in the morning measured with thin clothes. While measuring body weight, the individual was asked to remove his heavy clothes (coats, jackets, etc.), belongings in the pockets (wallet, key ring, phone, address book etc.) and shoes. Attention is given to place the feet on the balance and to ensure a balanced distribution of body weight to the two feet. The individual was asked to stand upright and without moving. The measurement was made with a sensitivity of 0.1 kg (100 g). Height: The height was measured with a stadiometer while the feet were side-by-side and the head was in the Frankfort plane. Body mass index (BMI): BMI was calculated by dividing subjects body weight by square of his/her height. [BMI = Body weight (kg)/height (m)²]. Waist circumference: The waist circumference was measured with a non-elastic tape measuring the mid-point between the lower rib and the crista iliac crest. Waist-to height ratio: It was calculated by the division of waist circumference (cm) into height (cm). Neck circumference: Neck circumference was measured with a non-elastic plastic band from the middle of the neck height between the middle cervical spine and the middle anterior neck with a sensitivity of 0.1 cm. In men with Adam's apple, it was measured just below the protrusion. BIA measurements: Body composition of the participants was determined with Tanita BC-418 MA (Tanita Corporation of America, Inc., Arlington Heights, IL) device. In order to make accurate measurements; metal jewelery on individuals, socks, clothes that will affect the measurement excessively were removed and information about the person's age, height, gender and whether they are dealing with regular sports activities were entered into the device. Then, individuals were removed from the instrument with their heels on the electrodes and the measurement was made. It was taken into consideration that participants did not perform intensive physical activity 24-48 hours before the measurement. It was observed that individuals did not have heavy physical activity 24-48 hours before the measurement, they were fasted for at least 4 hours, no alcohol was used 24 hours before, and they did not consume too much beverages (tea, coffee) before the measurement (at least 4 hours).
Biochemical parameters In the Endocrinology polyclinic; the patients were diagnosed with dyslipidemia by an endocrinologist and their fasting blood glucose (mg/dL), triglycerides (mg/dL), total cholesterol (mg/dL), HDL-cholesterol (mg/dL), LDL-cholesterol (mg/dL) levels were evaluated. Patients were selected according to the inclusion criteria and blood was drawn after fasting for at least 10-12 hours. Very low density lipoprotein (VLDL (mg/dL)), large-LDL (mg/dL), small-LDL (mg/dL) medium density lipoprotein (IDL (mg/dL)) (Mid A, B, C) values. After centrifugation, blood samples were kept in the freezer at -80°C in Erciyes University Endocrinology Service until analysis period. For patients who were not initially evaluated for insulin (mg/dL), some blood was collected and delivered to Erciyes University Blood Collection Department and studied at the Central Biochemistry Laboratory of Erciyes University. Fasting blood glucose, triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol levels were measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland). Insulin was measured by the ECLIA study method using the Roche Diagnostics (Mannheim, Germany). LDL subgroups were measured in serum samples using a Lipoprint System (Quantimetrix Inc., Redondo Beach, CA, USA). This system separates lipoproteins in a non-denaturing gel gradient of polyacrylamide based on net surface charge and size. The dye binds proportionally to the relative amount of cholesterol in each lipoprotein. After the electrophoresis, densitometric analyzes and proportional concentrations of lipoprotein classes and subclasses were calculated on the Lipoware software. In this system, VLDL, IDL corresponding to 3 midbands (Mid A, B, C) and 7 LDL subgroups: LDL-1 to -2 (large, bouyant, pattern A); LDL-3 to -7 (small, dense; pattern B). The system also gives the average LDL particle size. Type A if particle size was ≥268Â, medium level if particle size was 265-268Â, type B if particle size was ≤265Â.
- Conditions
- Dyslipidemias
- Being tested
- Low-fat and low-cholesterol diet
- Keywords
- Dyslipidemia, Low-Fat Low-Cholesterol Diet, LDL Sub-groups
- Medical subject headings
- Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-fat and low-cholesterol dietBehavioural
Low-fat (<30% of total energy) and low-cholesterol (<200mg/day) diet total of 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Low-fat, low-cholesterol diet | Other | Patients diagnosed with dyslipidemia by the endocrinologist were followed up for 12 weeks with a low-fat, low-cholesterol diet on a monthly basis, provided that they were suitable for each. Receives: Behavioral: Low-fat and low-cholesterol diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Baseline LDL subgroups at 12 weeks
LDL subgroups were measured in serum samples using a Lipoprint System (Quantimetrix Inc., Redondo Beach, CA, USA). This system separates lipoproteins in a non-denaturing gel gradient of polyacrylamide based on net surface charge and size. The dye binds proportionally to the relative amount of cholesterol in each lipoprotein. After the electrophoresis, densitometric analyzes and proportional concentrations of lipoprotein classes and subclasses were calculated on the Lipoware software. In this system, VLDL, IDL corresponding to 3 midbands (Mid A, B, C) and 7 LDL subgroups: LDL-1 to -2 (large, bouyant, pattern A); LDL-3 to -7 (small, dense; pattern B). The system also gives the average LDL particle size. Type A if particle size was ≥268Â, medium level if particle size was 265-268Â, type B if particle size was ≤265Â
Measured: Baseline and 12 weeks
Secondary outcomes (15)
Change in Baseline body weight at 12 weeks
Body weight in kilograms
Measured: Baseline and 12 weeks
Change in Baseline height at 12 weeks
Height in centimeter
Measured: Baseline and 12 weeks
Change in Baseline Body mass index (BMI) at 12 weeks
Body mass index (BMI) was calculated by dividing subjects body weight by square of his/her height. [BMI = Body weight (kg)/height (m)²]
Measured: Baseline and 12 weeks
Change in Baseline waist circumference at 12 weeks
Waist circumference in centimeter
Measured: Baseline and 12 weeks
Change in Baseline waist-to-height ratio at 12 weeks
Waist-to-height ratio was calculated by the division of waist circumference (cm) into height (cm)
Measured: Baseline and 12 weeks
Change in Baseline neck circumference at 12 weeks
Neck circumference in centimeter
Measured: Baseline and 12 weeks
Change in Baseline fat percentage at 12 weeks
Fat percentage (%) was measured by Tanita BC-418 MA (Tanita Corporation of America, Inc., Arlington Heights, IL)
Measured: Baseline and 12 weeks
Change in Baseline muscle mass at 12 weeks
Muscle mass was measured by Tanita BC-418 MA (Tanita Corporation of America, Inc., Arlington Heights, IL)
Measured: Baseline and 12 weeks
Change in Baseline blood sugar at 12 weeks
Blood sugar (mg/dL) was measured after at least 10-12 hours of fasting. Fasting blood glucose was measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland).
Measured: Baseline and 12 weeks
Change in Baseline triglycerides at 12 weeks
Triglycerides (mg/dL) was measured after at least 10-12 hours of fasting. Triglyceride was measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland). Triglycerides measurement is used in the diagnosis of dyslipidemia and the risk of cardiovascular disease increases above 150 mg/dL.
Measured: Baseline and 12 weeks
Change in Baseline total cholesterol at 12 weeks
Total cholesterol (mg/dL) was measured after at least 10-12 hours of fasting. Total cholesterol was measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland). Total cholesterol measurement is used in the diagnosis of dyslipidemia and the risk of cardiovascular disease increases above 200 mg/dL.
Measured: Baseline and 12 weeks
Change in Baseline HDL-cholesterol at 12 weeks
HDL-cholesterol (mg/dL) was measured after at least 10-12 hours of fasting. HDL-cholesterol was measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland). HDL cholesterol measurement is used in the diagnosis of dyslipidemia and the increase in HDL cholesterol reduces the risk of cardiovascular disease.
Measured: Baseline and 12 weeks
Change in Baseline LDL-cholesterol at 12 weeks
LDL-cholesterol (mg/dL) was measured after at least 10-12 hours of fasting. LDL-cholesterol levels was measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland). LDL-cholesterol measurement is used in the diagnosis of dyslipidemia and the risk of cardiovascular disease increases above 130 mg/dL.
Measured: Baseline and 12 weeks
Change in Baseline insulin at 12 weeks
LDL-cholesterol (mg/dL) was measured after at least 10-12 hours of fasting. Insulin was measured by the ECLIA study method using the Roche Diagnostics (Mannheim, Germany).
Measured: Baseline and 12 weeks
Change in Baseline blood pressure Levels at 12 weeks
Blood pressure was measured with a device called a sphygmomanometer while patients were at rest. High blood pressure is one of the most important risk factors for cardiovascular disease.
Measured: Baseline and 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2021
- Study start5 Sep 2017
- Primary completion5 Sep 2018
- Study completion25 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (33)Papers the sponsor has linked to this study.
- Other trials for DyslipidemiasStudies of the same condition, open and under way.
- More trials run by TC Erciyes UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- TC Erciyes University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Betül Cicek, TC Erciyes University
- Investigators
- Ülger Kaçar Mutlutürk, Phd, Principal investigator, TC Erciyes UniversityFahri Bayram, Prof.Dr., Study director, TC Erciyes University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04894318
- Sponsor's protocol ID
- TYL-2018-8497
- Status last verified
- May 2021
- First submitted
- 5 May 2021
- Last updated
- 20 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All off the individual
Publications
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr;18 Suppl 1:1-78. doi: 10.4158/ep.18.s1.1. No abstract available.
PubMed 22522068Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, Sabuncu T, Karaman A, Cesur M, Rizzo M, Toth PP, Gedik V. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014 Mar-Apr;8(2):206-16. doi: 10.1016/j.jacl.2013.12.011. Epub 2014 Jan 19.
PubMed 24636181Mahley RW, Pepin J, Palaoglu KE, Malloy MJ, Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase. High density lipoprotein characterization and gender-specific effects of apolipoprotein e genotype. J Lipid Res. 2000 Aug;41(8):1290-301.
PubMed 10946017Bedard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex Differences in the Impact of the Mediterranean Diet on LDL Particle Size Distribution and Oxidation. Nutrients. 2015 May 15;7(5):3705-23. doi: 10.3390/nu7053705.
PubMed 25988764El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007 Feb 6;49(5):547-53. doi: 10.1016/j.jacc.2006.09.043. Epub 2007 Jan 22.
PubMed 17276177Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010 Jun;56(6):967-76. doi: 10.1373/clinchem.2009.137489. Epub 2010 Apr 29.
PubMed 20431054Gerber PA, Nikolic D, Rizzo M. Small, dense LDL: an update. Curr Opin Cardiol. 2017 Jul;32(4):454-459. doi: 10.1097/HCO.0000000000000410.
PubMed 28426445Feingold KR. Introduction to Lipids and Lipoproteins. 2024 Jan 14. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK305896/
PubMed 26247089Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017;2017:1273042. doi: 10.1155/2017/1273042. Epub 2017 May 7.
PubMed 28572872Guay V, Lamarche B, Charest A, Tremblay AJ, Couture P. Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Metabolism. 2012 Jan;61(1):76-83. doi: 10.1016/j.metabol.2011.06.002. Epub 2011 Aug 3.
PubMed 21816443Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. No abstract available.
PubMed 31591002Schwingshackl L, Hoffmann G. Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients: a systematic review and meta-analysis. J Acad Nutr Diet. 2013 Dec;113(12):1640-61. doi: 10.1016/j.jand.2013.07.010. Epub 2013 Oct 17.
PubMed 24139973Wu L, Ma D, Walton-Moss B, He Z. Effects of low-fat diet on serum lipids in premenopausal and postmenopausal women: a meta-analysis of randomized controlled trials. Menopause. 2014 Jan;21(1):89-99. doi: 10.1097/GME.0b013e318291f5c2.
PubMed 23736858Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011 Oct 21;8:115. doi: 10.1186/1479-5868-8-115.
PubMed 22018588Zen V, Fuchs FD, Wainstein MV, Goncalves SC, Biavatti K, Riedner CE, Fuchs FC, Wainstein RV, Rhoden EL, Ribeiro JP, Fuchs SC. Neck circumference and central obesity are independent predictors of coronary artery disease in patients undergoing coronary angiography. Am J Cardiovasc Dis. 2012;2(4):323-30. Epub 2012 Oct 25.
PubMed 23173107
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Short Term Beneficıal Effects Of A Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Dyslipidemic Turkish Patients
- ClinicalTrials.gov ID
- NCT04894318
- Acronym / sponsor ID
- TYL-2018-8497
- Conditions
- Dyslipidemias
- Keywords
- Dyslipidemia, Low-Fat Low-Cholesterol Diet, LDL Sub-groups
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- TC Erciyes UniversityUniversity, hospital or other
- Study start
- 5 Sep 2017 (actual)
- Primary completion
- 5 Sep 2018 (actual)
- Study completion
- 25 Jul 2019 (actual)
- First posted
- 20 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare LDL sub-group concentration before and after a diet with low-fat and low-cholesterol prescribed to dyslipidemic patients for 12 weeks.
Detailed description
The study was conducted between January 2018-July 2019 in Erciyes University Health Application and Research Center. This study was planned as a clinical trial for treatment and 47 patients were included. All participants were given written consent. The study was evaluated to be ethically appropriate by Erciyes University Faculty of Medicine Clinical Research Ethics Committee.
A low-fat (<30% of total energy), and low-cholesterol (<200 mg/day) diet was planned for the participants at the baseline, according to the gender, lifestyle, working conditions, nutritional habits, BMI, concomitant diseases and risk conditions. The patients were called for monthly controls and followed up for a total of 12 weeks. When the patients admitted at the first and second months, Body Impedance Analyzer (BIA) measurements were performed and dietary adherence was controlled. If necessary, the energy requirements of the patients were re-calculated and their diets were re-newed and if the patients had any questions on the diet, they were answered. Blood samples were taken from the patients at the baseline and after 12 weeks and the effects of a low-fat, low-cholesterol diet on biochemical and anthropometric measurements were evaluated. Energy restricted diet were planed for overweight and obese patients (~ 500-1000 kcal/day). In addition, patients were recommended to walk at a moderate speed for at least 30-40 min per day.
Data Collection A questionnaire including socio-demographic characteristics, nutritional habits, physical activity status, and comorbid diseases was filled by the researcher. The food consumption frequency of the participants was evaluated by dividing the frequencies into four groups as consuming 5-6 times daily, consuming every other day, consuming 1-2 times a week and consuming 1-2 times a month or never at all. Food consumption records were also taken from each patient. Physical activity was questioned by the 'International Physical Activity Questionnaire (short form).
Statistical analysis The suitability of the data for normal distribution was evaluated by histogram, q-q graphs and Shapiro-Wilk test. Variance homogeneity was tested with Levene test. Two groups independent samples t-test and Mann-Whitney U-tests were used for quantitative variables. In the qualitative data, two repeated measurement comparisons were used with McNemar-Bowker test. The paired t-test and Wilcoxon tests were used in the quantitative data for two repeated measurements. Spearman analysis was used to evaluate the relationship between quantitative variables. Data analysis was performed by Turcosa Cloud (Turcosa Ltd Co) statistical software. Significance level was accepted as p<0.05.
Anthropometric measurements After the completing the questionnaire, anthropometric measurements were taken. Body weight: When the patient was in fasting state in the morning measured with thin clothes. While measuring body weight, the individual was asked to remove his heavy clothes (coats, jackets, etc.), belongings in the pockets (wallet, key ring, phone, address book etc.) and shoes. Attention is given to place the feet on the balance and to ensure a balanced distribution of body weight to the two feet. The individual was asked to stand upright and without moving. The measurement was made with a sensitivity of 0.1 kg (100 g). Height: The height was measured with a stadiometer while the feet were side-by-side and the head was in the Frankfort plane. Body mass index (BMI): BMI was calculated by dividing subjects body weight by square of his/her height. [BMI = Body weight (kg)/height (m)²]. Waist circumference: The waist circumference was measured with a non-elastic tape measuring the mid-point between the lower rib and the crista iliac crest. Waist-to height ratio: It was calculated by the division of waist circumference (cm) into height (cm). Neck circumference: Neck circumference was measured with a non-elastic plastic band from the middle of the neck height between the middle cervical spine and the middle anterior neck with a sensitivity of 0.1 cm. In men with Adam's apple, it was measured just below the protrusion. BIA measurements: Body composition of the participants was determined with Tanita BC-418 MA (Tanita Corporation of America, Inc., Arlington Heights, IL) device. In order to make accurate measurements; metal jewelery on individuals, socks, clothes that will affect the measurement excessively were removed and information about the person's age, height, gender and whether they are dealing with regular sports activities were entered into the device. Then, individuals were removed from the instrument with their heels on the electrodes and the measurement was made. It was taken into consideration that participants did not perform intensive physical activity 24-48 hours before the measurement. It was observed that individuals did not have heavy physical activity 24-48 hours before the measurement, they were fasted for at least 4 hours, no alcohol was used 24 hours before, and they did not consume too much beverages (tea, coffee) before the measurement (at least 4 hours).
Biochemical parameters In the Endocrinology polyclinic; the patients were diagnosed with dyslipidemia by an endocrinologist and their fasting blood glucose (mg/dL), triglycerides (mg/dL), total cholesterol (mg/dL), HDL-cholesterol (mg/dL), LDL-cholesterol (mg/dL) levels were evaluated. Patients were selected according to the inclusion criteria and blood was drawn after fasting for at least 10-12 hours. Very low density lipoprotein (VLDL (mg/dL)), large-LDL (mg/dL), small-LDL (mg/dL) medium density lipoprotein (IDL (mg/dL)) (Mid A, B, C) values. After centrifugation, blood samples were kept in the freezer at -80°C in Erciyes University Endocrinology Service until analysis period. For patients who were not initially evaluated for insulin (mg/dL), some blood was collected and delivered to Erciyes University Blood Collection Department and studied at the Central Biochemistry Laboratory of Erciyes University. Fasting blood glucose, triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol levels were measured by spectrophotometric method using Roche Diagnostics (Basel, Switzerland). Insulin was measured by the ECLIA study method using the Roche Diagnostics (Mannheim, Germany). LDL subgroups were measured in serum samples using a Lipoprint System (Quantimetrix Inc., Redondo Beach, CA, USA). This system separates lipoproteins in a non-denaturing gel gradient of polyacrylamide based on net surface charge and size. The dye binds proportionally to the relative amount of cholesterol in each lipoprotein. After the electrophoresis, densitometric analyzes and proportional concentrations of lipoprotein classes and subclasses were calculated on the Lipoware software. In this system, VLDL, IDL corresponding to 3 midbands (Mid A, B, C) and 7 LDL subgroups: LDL-1 to -2 (large, bouyant, pattern A); LDL-3 to -7 (small, dense; pattern B). The system also gives the average LDL particle size. Type A if particle size was ≥268Â, medium level if particle size was 265-268Â, type B if particle size was ≤265Â.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Low-fat, low-cholesterol diet | Other | Behavioral: Low-fat and low-cholesterol dietPatients diagnosed with dyslipidemia by the endocrinologist were followed up for 12 weeks with a low-fat, low-cholesterol diet on a monthly basis, provided that they were suitable for each. |
Who may qualify
- Ages
- 25 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Being diagnosed with dyslipidemia by an endocrinologist
- Those who do not have a history of diabetes, hyperthyroidism, hypothyroidism (including those who have hypothyroidism but receive replacement therapy)
- 25-65 years
- Body Mass Index (BMI) = 25-40 kg/m²
- Smoking three or less than three cigarettes a day
Key exclusion criteria (8 listed)
- Not being diagnosed with dyslipidemia
- Using a drug that affects the lipid profile
- Not being in the age range of 25-65
- BMI = 25-40 kg/m² not
- Smoking more than three cigarettes a day
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-fat and low-cholesterol dietLow-fat (<30% of total energy) and low-cholesterol (<200mg/day) diet total of 12 weeks | Behavioural | Low-fat, low-cholesterol diet |
Primary outcome
Change in Baseline LDL subgroups at 12 weeks
Time frame: Baseline and 12 weeks
LDL subgroups were measured in serum samples using a Lipoprint System (Quantimetrix Inc., Redondo Beach, CA, USA). This system separates lipoproteins in a non-denaturing gel gradient of polyacrylamide based on net surface charge and size. The dye binds proportionally to the relative amount of cholesterol in each lipoprotein. After the electrophoresis, densitometric analyzes and proportional concentrations of lipoprotein classes and subclasses were calculated on the Lipoware software. In this system, VLDL, IDL corresponding to 3 midbands (Mid A, B, C) and 7 LDL subgroups: LDL-1 to -2 (large, bouyant, pattern A); LDL-3 to -7 (small, dense; pattern B). The system also gives the average LDL particle size. Type A if particle size was ≥268Â, medium level if particle size was 265-268Â, type B if particle size was ≤265Â
15 secondary outcomes
Change in Baseline body weight at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline height at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline Body mass index (BMI) at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline waist circumference at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline waist-to-height ratio at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline neck circumference at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline fat percentage at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline muscle mass at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline blood sugar at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline triglycerides at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline total cholesterol at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline HDL-cholesterol at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline LDL-cholesterol at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline insulin at 12 weeks
Time frame: Baseline and 12 weeks
Change in Baseline blood pressure Levels at 12 weeks
Time frame: Baseline and 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2021.
- Results publication: PubMed 22522068Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr;18 Suppl 1:1-78. doi: 10.4158/ep.18.s1.1. No abstract available.
- Results publication: PubMed 24636181Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, Sabuncu T, Karaman A, Cesur M, Rizzo M, Toth PP, Gedik V. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014 Mar-Apr;8(2):206-16. doi: 10.1016/j.jacl.2013.12.011. Epub 2014 Jan 19.
- Results publication: PubMed 10946017Mahley RW, Pepin J, Palaoglu KE, Malloy MJ, Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase. High density lipoprotein characterization and gender-specific effects of apolipoprotein e genotype. J Lipid Res. 2000 Aug;41(8):1290-301.
- Results publication: PubMed 25988764Bedard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex Differences in the Impact of the Mediterranean Diet on LDL Particle Size Distribution and Oxidation. Nutrients. 2015 May 15;7(5):3705-23. doi: 10.3390/nu7053705.
- Results publication: PubMed 17276177El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007 Feb 6;49(5):547-53. doi: 10.1016/j.jacc.2006.09.043. Epub 2007 Jan 22.
- Results publication: PubMed 20431054Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010 Jun;56(6):967-76. doi: 10.1373/clinchem.2009.137489. Epub 2010 Apr 29.
- Results publication: PubMed 28426445Gerber PA, Nikolic D, Rizzo M. Small, dense LDL: an update. Curr Opin Cardiol. 2017 Jul;32(4):454-459. doi: 10.1097/HCO.0000000000000410.
- Results publication: PubMed 26247089Feingold KR. Introduction to Lipids and Lipoproteins. 2024 Jan 14. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK305896/
- Results publication: PubMed 28572872Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017;2017:1273042. doi: 10.1155/2017/1273042. Epub 2017 May 7.
- Results publication: PubMed 21816443Guay V, Lamarche B, Charest A, Tremblay AJ, Couture P. Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Metabolism. 2012 Jan;61(1):76-83. doi: 10.1016/j.metabol.2011.06.002. Epub 2011 Aug 3.
- Results publication: PubMed 31591002Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. No abstract available.
- Results publication: PubMed 24139973Schwingshackl L, Hoffmann G. Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients: a systematic review and meta-analysis. J Acad Nutr Diet. 2013 Dec;113(12):1640-61. doi: 10.1016/j.jand.2013.07.010. Epub 2013 Oct 17.
- TEMD Obezite, Dislipidemi, Hipertansiyon Çalışma Grubu' TEMD Dislipidemi Tanı ve Tedavi Kılavuzu', Ankara, Nisan 2019: 13-40 (in Turkish)Link provided by the sponsor.
- Türkiye Beslenme Rehberi TUBER 2015, T.C. Saglık Bakanlıgı Yayın No: 1031, Ankara 2016.Erisim:\[https://dosyasb.saglik.gov.tr/Eklenti/10915,tuberturkiyebeslenme-rehberipdf.pdf\], Date of access: 18.10.2018 (in Turkish).Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. All off the individual
Related trials for Dyslipidemias
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ülger Kaçar Mutlutürk, Phd principal investigator
TC Erciyes University
Fahri Bayram, Prof.Dr. study director
TC Erciyes University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low-fat and low-cholesterol diet in people with Dyslipidemias, run by TC Erciyes University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Baseline LDL subgroups at 12 weeks (time frame: Baseline and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04894318, which also lists 33 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2021.